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Micronutrients: do small things matter?
Introduction
It is increasingly and consistently realised that micronutrients have 
an important role to play in health and disease. Apart from the 
prevention of clinical deficiency syndromes, the fast developing 
field of immunonutrition has added yet another dimension to 
the importance of foods, nutrition and micronutrients in disease 
prevention and therapy. It is well known that micronutrients are 
involved in the prevention of nutritional deficiencies, immune humoral 
and cellular defence, regulation of gene expression during the acute 
phase response, antioxidant defence and prevention of chronic 
diseases.1 Despite these major developments on the importance of 
other aspects of micronutrient status, understanding of the exact 
role of the latter in critical illness remains elusive and ill defined, 
complicating decision-making on the part of the nutrition support 
practitioner.
In the critical care field it is well-known that nutrition support 
is a key component of therapy in these patients. Although great 
care is given to provide adequate and optimal carbohydrate, lipid 
and protein combinations, the vital role of micronutrients should 
not be overlooked.2 Despite the lack of clear guidelines regarding 
micronutrient requirements in the critically ill, a growing body of 
evidence (though conflicting at times) is emerging.  
Micronutrients in the critically ill patient
Nutritional support of the critically ill patient includes the daily provision 
of vitamins and trace elements. These compounds, collectively 
termed “micronutrients”, are essential not only as intermediaries 
in metabolism but also for their potential roles in cellular immunity, 
wound healing and antioxidant activity.3 Micronutrient deficiencies in 
critically ill patients may occur as pre-existing conditions in patients 
with poor nutritional status prior to hospitalisation or as a result of 
severe illness or the injury itself.2 Any injured patient will develop 
an acute phase response (APR) and a systemic inflammatory 
response syndrome (SIRS) with the production of various mediators, 
including cytokines, which modulate the metabolic response.4,5 
SIRS is associated with a redistribution of vitamins and trace 
elements from the circulating compartment to tissues and organs, 
which are involved in protein synthesis and immune cell production.6 
The circulating concentrations of most trace elements (iron, selenium, 
zinc) and of their carrier proteins decrease as do the water-soluble 
vitamins, whereas copper and manganese increase,6,7 causing a 
relative deficit in circulating antioxidants. In addition, trauma and 
burns patients typically experience extensive loss of biologic fluids 
through wound exudates, drains and haemorrhage, which contribute 
to negative micronutrient balances.5 These deficient states can 
adversely affect various biochemical processes and enzymatic 
functions, resulting in organ dysfunction, poor wound healing and 
altered immune status – all with deleterious patient outcomes.2 
Therefore attention to micronutrient requirements in the critically ill 
is imperative.
Micronutrients and the oxidative stress state
Oxidative stress has been implicated in the manifestations of critical 
illnesses, including ischaemia and reperfusion injury and systemic 
inflammatory states.8 The latter is increasingly being recognised as 
vital to the underlying pathophysiology of critical illness, particularly 
the development of organ failure.9 Oxidative stress is defined as 
“a state in which the level of toxic reactive oxygen intermediates 
(ROI)/reactive oxygen species (ROS) overcomes the endogenous 
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antioxidant defenses of the host”.8 Oxidative stress can result from 
either an excess in oxidant production, and/or depletion of antioxidant 
defenses.10,11 Protective antioxidant systems help defend against 
ROS-induced cellular damage. Oxidative stress is thought to increase 
in the presence of the APR because of the accompanying activation 
of neutrophils and macrophages and the subsequent release of 
free radicals,12 which may overwhelm defensive mechanisms and 
disturb the pro-oxidant-antioxidant balance in favour of the former, 
leading to potential damage.13 Besides ROS, another category of 
free radicals is derived from nitric oxide (NO) metabolism and is the 
normal byproduct of endothelial metabolism.6 Free radicals cause 
a cascade of intracellular events resulting in the release of nuclear 
factor-kappa B (NF-Κb) in the cytoplasm,14 and subsequently 
enabling the initiation of the transcription process. NF-κB controls 
the production of acute phase mediators such as tumour necrosis 
factor (TNF-α), interleukin 2 (IL-2), and IL-2 receptors, which in 
turn activate NF-κB, intensifying the inflammatory cascade.6 In this 
regard, selenium has been shown to downregulate NF-κB, thus 
limiting the extent of the APR15,16 whereas antioxidants in general are 
considered to limit the release of NF-κB caused by ROS.17 Oxidative 
stress can cause lipid peroxidation, damage to DNA, and cell death18 
and has been associated with sepsis, shock, mechanical ventilation, 
organ dysfunction, adult respiratory distress syndrome (ARDS) 
and surgery.13
Thus, critical illness is associated with increased ROS production (and 
thus increased oxidative stress), and on the other hand low levels of 
most antioxidant micronutrients (endogenous antioxidant defenses). 
Good and reliable methods of assessing overall antioxidant status 
are therefore important, but remain problematic. Measurement of 
individual micronutrients in the plasma is of limited value, whilst the 
measurements of total antioxidant capacity (TAC), though promising, 
have not yet been shown to have sufficient sensitivity or specificity 
for clinical use.19 Proof of an increased oxidative stress state is 
difficult to obtain based solely on measured levels of ROS, due to 
their short half-life.11 Evidence for an increased oxidative stress state 
in critically ill patients is seen indirectly through the measurement 
of the byproducts of ROS with cellular molecules. These patients 
demonstrate elevated levels of substances such as thiobarbituric 
acid-reacting substances (TBARS: byproducts of the interactions of 
lipids with ROS), DNA and proteins.2 Oxidative damage markers, such 
as malondialdehyde (MDA) or F2-isoprostanes, reflect the balance 
between oxidant stress and the body’s ability to cope with it,20 and 
are likely to be more useful than antioxidant protection markers in 
predicting outcome.21
Endogenous mechanisms work in a network-like fashion to neutralise 
the production of ROS in an attempt to counteract the deleterious 
effects thereof.2 Intracellular glutathione and nonenzymatic ROS 
scavengers (including vitamins such as ascorbic acid, β-carotene 
and α-tocopherol) form part of this highly evolved mechanism. 
Enzymatic systems [including superoxide dismutase (SOD), catalase 
and glutathione peroxidases (GSHPx)] then work synergistically 
to detoxify ROS further. These enzyme systems are dependant on 
minerals such as selenium, copper, zinc and manganese as important 
cofactors in these enzymatic reactions.2
Of all the antioxidants, special interest is being afforded to selenium 
as a result of recent supplementation trials. Selenium-dependant 
enzymes and selenoprotein P regulate immune and endothelial 
function. Four of the six known glutathione peroxidases play a 
significant role in antioxidant defenses.6 The mechanisms involved 
have been reviewed22 in detail and indicate that it is not necessarily 
selenium itself but rather the activity of selenium-dependant 
enzymes that are of crucial importance.
Micronutrient supplementation in critical illness
Research on micronutrient supplementation in the critically ill has 
focused mainly on five micronutrients: selenium, zinc, copper, 
vitamins C and E, and more recently also the vitamin B group.1,6 
The aims of supplementation can be described as provision of basic 
nutritional support (bearing in mind the increased requirements due 
to hypermetabolism and wound healing), prevention and correction 
of deficiencies, and modulation of the APR and immune responses 
by reinforcement of endogenous antioxidant defences.1 Establishing 
requirements in the critically ill has proven notoriously difficult 
and various sets of guidelines (each with their own limitations in 
a particular population) and proposals from various authors are 
available.5,23-29
Despite these guidelines and proposals little consensus exists as to 
“what to use when” and many questions remain regarding doses 
required, route and timing of replacement. It is also imperative to 
bear in the mind the potential for deleterious effects, i.e. “more is not 
necessarily better”. Micronutrients, especially trace elements and fat 
soluble vitamins, carry the risk of toxicity at high intake levels.5,6 
Nutrition support practitioners considering supplementing antioxidant 
micronutrients in critically ill patients should proceed with caution 
and consider the amounts of such micronutrients a patient is already 
receiving through an oral diet and/or enteral/parenteral nutritional 
support. Inappropriate antioxidant micronutrient supplementation 
has the potential for creating a pro-oxidant microenvironment that 
may have as much potential for harm as for benefit in the well-
nourished patient. 
A growing body of evidence is emerging that demonstrates the 
potential benefits of micronutrient (and specifically antioxidant) 
supplementation in critically ill patients. 
Synthesis of the evidence
Despite two published systematic reviews already available in the 
literature,9,30 the sum-total of available evidence (including the 
outcome of these two meta-analyses) still indicates that the exact 
micronutrient requirements of the critically ill patient and related 
practice issues remain uncertain. Since the systematic review by 
Heyland et al9 was published in 2005, several trials were conducted 
(including larger multi-centre trials) prompting our group to explore 
the questions once more by aggregating the latest trial data and 
results with those of the older trials, with the aim of obtaining better 
clarity and further answers.31
The systematic review and meta-analysis undertaken by our group31 
substantially builds on the initial very important review by Heyland et 
al9 by including seven new trials, including the first four multi-centre 
randomised controlled trials in this area of research.32-35 This updated 
review31 indicates and supports previous findings9 that micronutrient 
supplementation in the critically ill may be associated with a 
reduction in overall mortality, and specifically 28 day mortality. 
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Micronutrient supplementation in the updated systematic review31 
was not associated with a reduction in infectious complications, 
similar to the findings of Heyland et al.9 This finding could possibly 
indicate that the mortality effect observed was mediated by other 
mechanisms (e.g. improved organ function). The updated review31 
was the first to report on LICU and LOS and found that these 
outcomes were unaffected by micronutrient supplementation. 
In sub-group analyses of the updated review,31 single nutrients were 
associated with borderline statistical significance (p = 0.06) in terms 
of mortality, whilst a sensitivity analysis of combined micronutrients 
indicated a significant reduction in mortality (p = 0.006). Although 
in contrast to the Heyland et al9 findings (i.e. single nutrients were 
associated with a significant reduction in mortality; combined 
micronutrients were not), the findings of the updated review would 
appear to support prior hypotheses and the rationale underlying the 
use of combinations of micronutrients, based on observations of the 
biochemical properties of the endogenous antioxidant network and 
the fact that micronutrients depend on each other for regeneration 
in a continued spiral.1 
The updated review did not find clear evidence that parenteral is 
superior to enteral administration in terms of clinical outcomes, 
in contrast to the Heyland et al9 review that did find a significant 
reduction in mortality associated with parenteral administration of 
antioxidants. The vast majority of trials available in the literature 
delivered micronutrients intravenously, with the intravenous route 
seen as the only reliable method by which micronutrients can be 
administered in the critically ill.2 Absorption by the enteral route 
in critically ill patients is unpredictable due to bowel oedema, 
bowel ischaemia, haemodynamic instability, fluid resuscitation 
and alterations in blood supply.36 On the other hand, delivering 
micronutrients to the gut may be beneficial through the attenuation 
of the local gut inflammatory response,37 indicating that both routes, 
theoretically at least, do have their advantages.9 Given the major role 
of the gastrointestinal tract as a source of cytokine and leukocyte 
activation and ROS formation, the provision of key nutrients directly 
to the gastrointestinal tract makes biological sense.38 It is thus 
proposed that future studies investigate the use of both parenteral 
and enteral administration of micronutrients to maximise the 
opportunity of demonstrating a treatment effect, if one truly exists.
The current evidence and updated review confirms that timing, 
duration and dosing are key factors to ensure optimal clinical 
benefit. The timing of micronutrient supplementation is important 
and is probably a key factor as the repletion of micronutrients, and 
specifically antioxidants, would probably achieve a greater efficacy 
if given before massive oxidative injury (e.g. severe sepsis or septic 
shock).39 Despite the fact that no studies could be found comparing 
early to late micronutrient supplementation in the critically ill, it is 
reasonable to conclude that micronutrient supplementation should 
begin early in the course of critical illness to offset the deleterious 
effects of ROS. Another important factor to consider is the duration 
of supplementation, which should be sufficient to produce optimal 
clinical benefit.
In terms of micronutrient doses (Table I) the updated systematic 
review31 has highlighted the fact that there is still not clarity 
regarding optimal doses and which patients will benefit most 
(or will be adversely affected), and that further large multi-centre 
trials (including dose-finding trials) are necessary. It is of obvious 
importance to find the optimal dose for micronutrients administration, 
which is effective without producing a pro-oxidant effect.
Importantly, the vast majority of trials avaiable in the literature reported 
no adverse/deleterious effects of micronutrient administration, 
with the exception of one trial that deserves mention.35 This study 
by Siriwardena et al,35 conducted in patients with severe acute 
pancreatitis, indicated a trend towards worse outcome in the 
treatment arm of the study (although results were not statistically 
significant and not demonstrably treatment related). The outcome 
of this study warrants caution, at least in patients with severe acute 
pancreatitis. In general terms, practitioners will be well served by 
remembering “more is not necessarily better”. Micronutrients may 
have dose-response curves with toxicity risk at high levels of intake. 
Zinc toxicity has been reported with doses of over 50 mg per day42 
Table I: Recommended doses and doses used in RCTs of selected micronutrients in critical illness
Micronutrient
(MN)
RDA for 
oral feeding 
(daily)23,24
UL40,41
Recommendations for PN
Proposed supplements 
(in addition to MNs provided by feeding)
Doses in RCTs
AMA 
197925,26
Shenkin 
199527
FDA  
200028
Berger 20065 Fuhrman 
2002
(/d)29
Major trauma 
(5d)
Major burns
(14-21d)
Vitamin C
(mg)
60 2000 100 100 200 1000 (IV) 1000 (IV) 500-3000
500-3000 (IV)
133-500 (EN)
Vitamin E
(mg)
8–10 1000 10 10 10 100 (EN) 100 (EN)
400 (IV)
40–1000 (EN)
50-400 (IV)
50-1350 (EN)
Selenium
(µg)
55–70 400 30–60 60 - 300 (IV) 500 (IV) 100–400 200-4000 (IV)
Zinc
(mg)
12–15 40 2.5–4 6.5 - 20 (IV) 30 (IV) 10–30 12-37.5 (IV)
Copper
(mg)
2 10 0.5–1.5 1.3 - - 4 (IV) - 2.5-3.75 (IV)
AMA: American Medical Association; d: day; EN: Enteral nutrition; FDA: Food and Drug Administration; IV: Intravenous; MN: Micronutrient; PN: Parenteral nutrition; RCT: Randomised controlled trial; RDA: Recommended dietary 
allowance for healthy people; UL: Tolerable upper intake level (general population)
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and an upper limit of intake of selenium in the diet has been set at 
400 µg (5 µg/kg) per day (although a no observable effect level of 800 
µg per day has been proposed).24 An upper limit for safe short-term 
intravenous supplementation of 750-1000 µg selenite per day in the 
critically ill has been suggested22 with a dose of 800 µg of selenium 
per day given via the combined IV and enteral route documented 
to be safe in a dose-finding study.43 Results of a meta-analysis of 
19 RCTs in the community suggest that high dosages of vitamin 
E increase risk of all-cause mortality, and this dose-dependant 
increase begins at 150 IU/day.44 It is not clear to what extent all these 
considerations apply to the critically ill, but certainly should warrant 
a word of caution. More dose-finding trials are therefore required to 
establish optimal doses.
Conclusions
The current evidence does suggest potential benefit of micronutrient 
supplementation in critically ill adults in terms of some clinical 
outcomes, but also highlights that caution is warranted in terms of 
micronutrients administered, doses and specific patient populations 
targeted as nutrient interactions and risk of toxicity are not clearly 
defined in critical illness. Once more the conclusion is that there 
is a need for more large multi-centre prospective randomised 
controlled trials to assess the effects of different types and doses 
of micronutrient supplementation in selected groups of patients 
with different types of critical illness, with a few such trials already 
underway.38,45 It has been suggested that targeting the appropriate 
patient populations most likely to benefit (i.e. the more severely ill 
patients), considering the route of delivery (possibly a combination 
of parenteral and enteral) as well as attention to doses administered 
might maximise the opportunity of demonstrating a treatment effect, 
if one truly exists. In practical terms it is clear that micronutrients 
should be provided at, at least, the current available recommended 
doses to prevent overt clinical deficiencies. For other claims/
indications and higher doses the literature consistently indicates 
that the risk (adverse effects) to benefit (mortality) ratio may be 
favourable, and if such higher doses are used in practice it should be 
within the dose range that the current experience covers and for the 
clinical settings studied only.
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